Seminars in Thoracic and Cardiovascular Surgery: Pediatric Cardiac Surgery Annual
Volume 3, Issue 1 , Pages 63-81 , January 2000

Pathobiology of pulmonary hypertension: Impact on clinical management

References 

  1. Rabinovitch M, Haworth SG, Castaneda AR, et al.  Lung biopsy in congenital heart disease: A morphometric approach to pulmonary vascular disease. Circulation. 1978;58:1107–1122
  2. Meyrick B, Reid L. Ultrastructural findings in lung biopsy material from children with congenital heart defects. Am J Pathol. 1980;101:527–537
  3. Rabinovitch M, Keane JF, Norwood WI, et al.  Vascular structure in lung tissue obtained at biopsy correlated with pulmonary hemodynamic findings after repair of congenital heart defects. Circulation. 1984;69:655–667
  4. Hickey PR, Hansen DD, Wessel DL, et al.  Blunting of stressing responses of the pulmonary circulation of infants by fentanyl. Anesth Analg. 1985;64:1137–1142
  5. Bush A, Bust CM, Knight WB, et al.  Modification of pulmonary hypertension secondary to congenital heart disease with prostacyclin therapy. Am Rev Resp Dis. 1987;136:167–170
  6. Ivy DD, Kinsella JP, Wolfe RR, et al.  Atrial natriuretic peptide and nitric oxide in children with pulmonary hypertension after surgical repair of congenital heart disease. Am J Cardiol. 1996;77:102–105
  7. Wessel DL, Adatia I. Clinical applications of inhaled nitric oxide in children with pulmonary hypertension. Adv Pharmacol. 1995;34:475–504
  8. Houde C, Bohn DJ, Freedom RM, et al.  Profile of paediatric patients with pulmonary hypertension judged by responsiveness to vasodilators. Br Heart J. 1993;70:461–468
  9. Viles P, Ongley P, Titus J. The spectrum of pulmonary vascular disease in transposition of the great arteries. Circulation. 1969;40:31–41
  10. Newfeld EA, Paul MH, Muster AJ, et al.  Pulmonary vascular disease in complete transposition of the great arteries: A study of 200 patients. Am J Cardiol. 1974;34:75–82
  11. Waldman JD, Paul MH, Newfeld EA. Transposition of the great arteries with intact ventricular septum and patent ductus arteriosus. Am J Cardiol. 1977;39:232–238
  12. Berman W, Whitman V, Pierce WS, et al.  The development of pulmonary vascular obstructive disease after successful Mustard operation in early infancy. Circulation. 1978;58:181–185
  13. Iverson RE, Lind LE, Kegel S. The diagnosis of progressive pulmonary vascular disease in children with ventricular septal defects. J Pediatr. 1966;68:594–600
  14. Newfeld EA, Sher M, Paul MH. Pulmonary vascular disease in complete artioventricular canal defect. Am J Cardiol. 1977;39:721–726
  15. Clapp S, Perry BL, Farooki ZO, et al.  Down's Syndrome, complete atrioventricular canal and pulmonary vascular obstructive disease. J Thorac Cardiovasc Surg. 1990;100:115–121
  16. Rabinovitch M, Keane JF, Fellows KE, et al.  Quantitative analysis of the pulmonary wedge angiogram in congenital heart defects: Correlation with hemodynamic data and morphometric findings in lung biopsy tissue. Circulation. 1981;63:152–164
  17. Rabinovitch M, Castenada AR, Reid L. Lung biopsy with frozen section as a diagnostic aid in patients with congenital heart defects. Am J Cardiol. 1981;47:77–84
  18. Juaneda E, Haworth SG. Pulmonary vascular structure in patients dying after a Fontan procedure: The lung as a risk factor. Br Heart J. 1984;52:575–580
  19. Rabinovitch M, Bothwell T, Hayakawa BN, et al.  Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension: A correlation of light with scanning electron microscopy and transmission electron microscopy. Lab Invest. 1986;55:632–653
  20. Rabinovitch M, Andrew M, Thom H, et al.  Abnormal endothelial factor VIII associated with pulmonary hypertension and congenital heart defects. Circulation. 1987;76:1043–1052
  21. Fuse S, Kamiya T. Plasma thromboxane B2 concentration in pulmonary hypertension associated with congenital heart disease. Circulation. 1994;90:2952–2955
  22. Turner-Gomes SO, Andrew M, Coles J, et al.  Abnormalities in von Willebrand factor and antithrombin III after cardiopulmonary bypass operations for congenital heart disease. Thorac Cardiovasc Surg. 1992;103:87–97
  23. Turner-Gomes SO, Boudreau N, Rabinovitch M. Effect of ambient oxygen changes on platelet activating factor production by fetal ovine endothelial cells. Prostaglandins. 1991;41:463–472
  24. Cutz E, Chan W, Wong V, et al.  Pulmonary neuroendocrine cells in normal human lung and in pulmonary hypertension. Lab Invest. 1986;54:14A; (abstr)
  25. Allen KM, Wharton J, Polak JM, et al.  A study of nerves containing peptides in the pulmonary vasculature of healthy infants and children and of those with pulmonary hypertension. Br Heart J. 1989;62:353–360
  26. Youngson C, Nurse C, Yeger H, et al.  Oxygen sensing in airway chemoreceptors. Nature. 1993;365:153–155
  27. Schindler MB, Bohn DJ, Bryan AC, et al.  Increased respiratory system resistance in bronchial smooth muscle hypertrophy in children with acute postoperative pulmonary hypertension. Am J Respir Crit Care Med. 1995;152:1347–1352
  28. Dinh Xuan AT, Higgenbottam TW, Clelland C, et al.  Impairment of pulmonary endothelium-dependent relaxation in patients with Eisenmenger's syndrome. Br J Pharmacol. 1990;99:9–10
  29. Adatia I, Haworth SG. Circulating endothelin levels in children with congenital heart disease. Br Heart J. 1993;69:233–236
  30. Celermajer DS, Cullen S, Deanfield JE. Impairment of endothelium-dependent pulmonary artery relaxation in children with congenital heart disease and abnormal pulmonary hemodynamics. Circulation. 1993;87:440–446
  31. Yoshibayashi M, Nishioka K, Nakao K, et al.  Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation. Circulation. 1991;84:2280–2285
  32. Chang H, Wu G-J, Wang S-M, et al.  Plasma endothelin levels and surgically correctable pulmonary hypertension. Ann Thorac Surg. 1993;55:450–458
  33. Jones PL, Cowan KN, Rabinovitch M. Induction of tenascin and fibronectin are features associated with increased smooth muscle cell proliferation during the development of progressive pulmonary hypertension in children. Am J Pathol. 1997;150:1349–1360
  34. Jones PL, Crack J, Rabinovitch M. Regulation of tenascin-C, a vascular smooth muscle cell survival factor that interacts with the avβ3 integrin to promote epidermal growth factor receptor phosphorylation and growth. J Cell Biol. 1997;139:279–293
  35. Jones PL, Rabinovitch M. Tenascin-C is induced with progressive pulmonary vascular disease in rats is functionally related to increased smooth muscle cell proliferation. Circ Res. 1996;79:1131–1142
  36. Boudreau N, Turley E, Rabinovitch M. Fibronectin, hyaluronan and a hyaluronan binding protein contribute to increased ductus arteriosus smooth muscle cell migration. Dev Biol. 1991;143:235–247
  37. Clausell N, Rabinovitch M. Upregulation of fibronectin synthesis by interleukin-1β in coronary artery smooth muscle cells is associated with the development of the post-cardiac transplant arteriopathy in piglets. J Clin Invest. 1992;92:1850–1858
  38. Botney MD, Bahadori L, Gold LI. Vascular remodeling in primary pulmonary hypertension. Potential role for transforming growth factor-β. Am J Pathol. 1994;144:286–295
  39. Botney MD, Liptay MJ, Kaiser LR, et al.  Active collagen synthesis by pulmonary arteries in human primary pulmonary hypertension. Am J Pathol. 1993;143:121–129
  40. Botney MD, Kaiser LR, Cooper JD, et al.  Extracellular matrix protein gene expression in atherosclerotic hypertensive pulmonary arteries. Am J Pathol. 1992;140:357–364
  41. Tuder RM, Groves B, Badesch DB, et al.  Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol. 1994;144:275–285
  42. Rendas A, Lennox S, Reid L. Aortopulmonary shunts in growing pigs. J Thorac Cardiovasc Surg. 1979;77:109–118
  43. Boucek MM, Chang R, Synhorst DP. Hemodynamic consequences of inotropic support with digoxin and amrinone in lambs with ventricular septal defect. Pediatr Res. 1985;19:887–891
  44. Wong J, Vanderford PA, Winters J, et al.  Endothelin b receptor antagonists produce pulmonary vasodilation in intact newborn lambs with pulmonary hypertension. J Cardiovasc Pharmacol. 1995;25:207–215
  45. Schnader J, Schloo BL, Anderson W, et al.  Chronic pulmonary hypertension in sheep: Temporal progression of lesions. J Surg Res. 1996;62:243–250
  46. Fasules JW, Tryka AF, Chipman CW, et al.  Pulmonary hypertension and arterial changes in calves with a systemic-to-left pulmonary artery connection. J Appl Physiol. 1994;77:867–875
  47. Todorovich-Hunter L, Johnson DJ, Ranger P, et al.  Altered elastin and collagen synthesis associated with progressive pulmonary hypertension induced by monocrotaline: A biochemical and ultrastructural study. Lab Invest. 1988;58:184–195
  48. Todorovich-Hunter L, Dodo H, Ye C, et al.  Increased pulmonary artery elastolytic activity in adult rats with monocrotaline-induced progressive hypertensive pulmonary vascular disease compared with infant rats with nonprogressive disease. Am Rev Respir Dis. 1992;146:213–223
  49. Maruyama K, Ye C, Woo M, et al.  Chronic hypoxic pulmonary hypertension in rats and increased elastolytic activity. Am J Physiol. 1991;261:H1716–H1726
  50. Ye C, Rabinovitch M. Inhibition of elastolysis by SC-37698 reduces development and progression of monocrotaline pulmonary hypertension. Am J Physiol. 1991;261:H1255–H1267
  51. Zhu L, Hinek A, Wigle D, et al.  The vascular elastase which governs the development and progression of pulmonary hypertension is related to adipsin. Mol Biol Cell. 1993;4:410a; (abstr)
  52. Hornebeck W, Brechemier D, Soleilhac JM, et al.  Studies on rat aorta smooth muscle cells' elastase activity. In:  Reddi AH editors. Extracellular Matrix: Structure and Function. New York, NY: Liss; 1985;p. 269–282
  53. Kobayashi J, Wigle D, Childs T, et al.  Serum-induced vascular smooth muscle cell elastolytic activity through tyrosine kinase intracellular signalling. J Cell Physiol. 1994;160:121–131
  54. Thompson K, Kobayashi J, Childs T, et al.  Endothelial and serum factors which include apolipoprotein A1 tether elastin to smooth muscle cells inducing serine elastase activity via tyrosine kinase-mediated transcription and translation. J Cell Physiol. 1998;174:78–89
  55. Thompson KE, Rabinovitch M. Induction of vascular elastase is mediated by integrins and is associated with phosphorylation of focal adhesion kinase and activation of the transcription factor AML-1. Mol Biol Cell. 1996;7(suppl):588a; (abstr)
  56. Wigle D, Thompson K, Yablonsky S, et al.  AML1-like transcription factor induces serine elastase activity in ovine pulmonary artery smooth muscle cells. Circ Res. 1998;83:252–263
  57. Nuchprayoon I, Meyers S, Scott LM, et al.  PEBP2/CBF, the murine homolog of the human myeloid AML1 and PEBP2β/CBFβ proto-oncoproteins, regulates the murine myeloperoxidase and neutrophil elastase genes in immature myeloid cells. Mol Cell Biol. 1994;14:5558–5568
  58. Mitani Y, Zaidi SHE, Dufourcq P: Nitric oxide reduces vascular smooth muscle cell elastase activity through cGMP-mediated suppression of ERK phosphorylation and AM1B nuclear partitioning. FASEB J (in press)
  59. Thompson K, Rabinovitch M. Exogenous leukocyte and endogenous elastases can mediate mitogenic activity in pulmonary artery smooth muscle cells by release of extracellular matrix-bound basic fibroblast growth factor. J Cell Physiol. 1996;166:495–505
  60. Saksela O, Rifkin DB. Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic degradation. J Cell Biol. 1990;107:743–751
  61. Taipale J, Lohi J, Saarinen J, et al.  Human mast cell chymase and leukocyte elastase release latent transforming growth factor-β1 from the extracellular matrix of cultured human epithelial and endothelial cells. J Biol Chem. 1995;270:4689–4696
  62. Meiners S, Marone M, Rittenhouse JL, et al.  Regulation of astrocytic tenascin by basic fibroblast growth factor. Dev Biol. 1993;160:480–493
  63. Jones PL, Jones FS, Zhou B, et al.  Denatured type I collagen induction of vascular smooth muscle cell tenascin-C gene expression is dependent upon a β3 integrin-mediated mitogen-activated protein kinase pathway and a 122 bp promoter element. J Cell Sci. 1999;112:435–445
  64. Cowan KN, Jones PL, Rabinovitch M. Regression of hypertrophied rat pulmonary arteries in organ culture is associated with suppression of proteolytic activity, inhibition of tenascin-C and smooth muscle cell apoptosis. Circ Res. 1999;84:1223–1233
  65. Cowan K, Jones PL, Rabinovitch M. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression of vascular disease. J Clin Invest. 2000;105:21–34
  66. Cowan KN, Heibut A, Humpl T, et al.  Elastase inhibition induces a smooth muscle cell apoptotic response mediating reversal of progressive pulmonary vascular disease in rats. Circulation. 1999;100(suppl):I-484; (abstr)
  67. Hinek A, Molossi S, Rabinovitch M. Functional interplay between interleukin-1 receptor and elastin binding protein regulates fibronectin production in coronary artery smooth muscle cells. Exp Cell Res. 1996;225:122–131
  68. Zhu L, Dagher E, Johnson DJ, et al.  A developmentally regulated program restricting insolubilization of elastin and formation of laminae in the fetal lamb ductus arteriosus. Lab Invest. 1993;68:321–331
  69. Oho S, Rabinovitch M. Post-cardiac transplant arteriopathy in piglets is associated with fragmentation of elastin and increased activity of a serine elastase. Am J Pathol. 1994;145:202–210
  70. Cowan B, Baron O, Crack J, et al.  Elafin, a serine elastase inhibitor, attenuates post-cardiac transplant coronary arteriopathy and reduces myocardial necrosis in rabbits following heterotopic cardiac transplantation. J Clin Invest. 1996;97:2452–2468
  71. Cowan B, Molossi S, Coulber C, et al.  Interleukin (IL)-1β stimulated fibronectin synthesis in coronary smooth muscle cells requires endogenous vascular elastase activity. Mol Biol Cell. 1994;5(suppl):429a; (abstr)
  72. Molossi S, Elices M, Arrhenius T, et al.  Blockade of very late antigen-4 integrin binding to fibronectin with connecting segment-1 peptide reduces accelerated coronary arteriopathy in rabbit cardiac allografts. J Clin Invest. 1995;95:2601–2610
  73. Molossi S, Elices M, Arrhenius T, et al.  Lymphocyte transendothelial migration toward smooth muscle cells in interleukin-1β stimulated co-cultures is related to fibronectin interactions with α4β1 and α5β1 integrins. J Cell Physiol. 1995;164:620–633
  74. Zhou B, Boudreau N, Coulber C, et al.  Microtubule-associated protein 1 light chain 3 is a fibronectin mRNA-binding protein linked to mRNA translation in lamb vascular smooth muscle cells. J Clin Invest. 1997;100:3070–3082
  75. Mason CAE, Bigras J-L, O'Blenes SB, et al.  Gene transfer in utero biologically engineers a patent ductus arteriosus in lambs by arresting fibronectin-dependent neointimal formation. Nature Med. 1999;5:176–188
  76. Mason CAE, Chang P, Fallery C, et al.  Nitric oxide mediates LC-3 dependent regulation of fibronectin synthesis in ductus arteriosus smooth muscle cells. FASEB J. 1999;13:1423–1434
  77. Chen SJ, Chen YF, Meng QC, et al.  Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol. 1995;79:2122–2131
  78. Li H, Chen SJ, Chen YF, et al.  Enhanced endothelin-1 and endothelin receptor gene expression in chronic hypoxia. J Appl Physiol. 1994;77:1451–1459
  79. Giaid A, Yanagisawa M, Langleben D, et al.  Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;238:1732–1739
  80. Morrell NW, Morris KG, Stenmark KR. Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. Am J Physiol. 1995;269:H1186–H1194
  81. Barst RJ, Rubin LJ, Long WA, et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996;334:296–302
  82. Voelkel NF, Hoeper M, Maloney J, et al.  Vascular endothelial growth factor in pulmonary hypertension. Ann NY Acad Sci. 1996;796:2186–2193
  83. Loyd JE, Butler MG, Foroud TM, et al.  Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med. 1995;152:93–97
  84. Morse JH, Jones AC, Barst RJ, et al.  Mapping of familial primary pulmonary hypertension locus (PPH1) to chromosome 2q31-q32. Circulation. 1997;95:2603–2613
  85. Wagenvoort CA, Heath D, Edwards JE. The Pathology of Pulmonary Vasculature. Springfield, IL: Charles C. Thomas Publishers; 1964;
  86. Rabinovitch M. Quantitative structural analysis of the pulmonary vascular bed in congenital heart defects. In:  Engle MA editors. Pediatric Cardiovascular Disease. Philadelphia, PA: F.A. Davis Co; 1981;p. 149–169
  87. Rabinovitch M. It all begins with EVE (endogenous vascular elastase). Isr J Med Sci. 1996;32:803–808

☆ Address reprint requests to Marlene Rabinovitch, MD, Director, Division of Cardiovascular Research, The Hospital for Sick Children, 555 University Ave, Toronto, Ontario, Canada M5G 1X8.

PII: S1092-9126(00)70008-1

Seminars in Thoracic and Cardiovascular Surgery: Pediatric Cardiac Surgery Annual
Volume 3, Issue 1 , Pages 63-81 , January 2000

Article Tools